Valuation : Alkermes plc

Market Cap 8.2B 7.04B 6.59B 6.04B 11.37B 784B 11.4B 78.07B 30.52B 395B 30.8B 30.14B 1,307B P/E 2026 *
-95.9x
P/E 2027 * 67.3x
Enterprise Value 8.95B 7.68B 7.19B 6.58B 12.4B 855B 12.44B 85.15B 33.29B 431B 33.59B 32.87B 1,425B EV / Sales 2026 *
4.9x
EV / Sales 2027 * 4.56x
Free-Float
89.45%
Yield 2026 *
-
Yield 2027 * -
1 day-0.53%
1 week+1.83%
Current month-0.18%
1 month-7.26%
3 months+28.38%
6 months+62.46%
Current year+74.77%
1 week 47.64
Extreme 47.64
49.58
1 month 47.33
Extreme 47.33
51.66
Current year 27
Extreme 27
55.67
1 year 25.16
Extreme 25.165
55.67
3 years 22.01
Extreme 22.01
55.67
5 years 21.24
Extreme 21.24
55.67
10 years 11.98
Extreme 11.98
71.22
Manager TitleAgeSince
Chief Executive Officer 53 01/08/2026
Director of Finance/CFO 53 15/09/2025
Chief Tech/Sci/R&D Officer 58 30/05/2017
Director TitleAgeSince
Chairman 64 01/09/2011
Director/Board Member 74 26/05/2016
Director/Board Member 63 30/03/2018
Date Insider Type Main position Quantity % Market Cap.
17/8/26 Sell

Executive/Senior Manager

-7,576 0.0045%
5/8/26 Free

Chief Executive Officer

217,534 0.1297%
3/8/26 Sell

Compliance Officer

-2,034 0.0012%
Change 5-day change 1-year change 3-year change Capi.($)
-0.53%+1.83%+67.18%+79.98% 8.2B
-0.24%-0.64%+3.30%+23.74% 51.14B
+2.65%+4.45%+481.36%+567.32% 47.4B
+0.33%+2.47%+38.97%+19.80% 43.19B
-0.88%+0.90%+24.11%+87.74% 42.35B
-2.27%-3.02%+14.22%+51.50% 33.23B
-1.21%-0.17%+29.16%+135.38% 17.07B
-0.36%-2.14% - - 16.38B
-0.19%+0.03%+12.37%+28.64% 14.76B
+0.44%+1.70%+82.07%+47.92% 14.15B
Average -0.22%+0.75%+83.64%+115.78% 28.79B
Weighted average by Cap. -0.04%+1.07%+105.18%+141.64%

Financials

2026 *2027 *
Net sales 1.82B 1.57B 1.47B 1.34B 2.53B 174B 2.54B 17.37B 6.79B 87.84B 6.85B 6.7B 291B 1.94B 1.67B 1.56B 1.43B 2.7B 186B 2.7B 18.51B 7.24B 93.62B 7.3B 7.14B 310B
Net income -89.92M -77.19M -72.26M -66.17M -125M -8.59B -125M -856M -335M -4.33B -338M -330M -14.32B 120M 103M 96.67M 88.52M 167M 11.49B 167M 1.14B 447M 5.79B 452M 442M 19.16B
Net Debt 744M 639M 598M 547M 1.03B 71.05B 1.03B 7.08B 2.77B 35.81B 2.79B 2.73B 119B 670M 575M 538M 493M 929M 63.98B 931M 6.38B 2.49B 32.25B 2.52B 2.46B 107B
Logo Alkermes plc
Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.
Employees
2,050
Date Price Change Volume
27/08/26 USD 48.90 -0.53% 2,119,395
26/08/26 USD 49.16 -0.10% 660,876
25/08/26 USD 49.21 +0.70% 1,127,442
24/08/26 USD 48.87 +1.12% 1,296,669
21/08/26 USD 48.33 +0.65% 939,640
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
48.90USD
Average target price
56.00USD
Spread / Average Target
+14.52%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALKS Stock